SCHOFIELD, Wis., June 10, 2009 (GLOBE NEWSWIRE) -- PuraMed Bioscience, Inc. (OTCBB:PMBS), a pharmaceutical company engaged in the development and marketing of a line of revolutionary, new, non-prescription medicines targeting major consumer health needs including the treatment of migraine headaches, insomnia and tension-type headaches, announced today that they have completed their first production run of their LipiGesic(tm)-M migraine relief product for commercial resale. This will provide the company with its first opportunity to generate revenue.
As a result of this milestone, PuraMed will be attending the NACDS Marketplace Conference in Boston 6/29-7/1. NACDS Marketplace Conference is the largest and most powerful convergence of drug, food, mass, club and value retailing in the United States, if not the world (www.nacdsmarketplace.org). This conference will lay the ground work for our retail launch of LipiGesic-M.
In addition, progress continues on the production efforts for our direct response television commercial featuring LipiGesic-M. Our initial indicators suggest that our commercial will be ready for airing and test marketing no later than the beginning of the fourth quarter 2009.
In response to the achievement of this milestone and the other significant progress, Russ Mitchell, CEO said, "The completion of our first commercial run of LipiGesic-M is a significant event for PuraMed. This will move our company forward from a pre-revenue stage to a revenue generating organization. This event, when combined with our progress on the direct response commercial and the exposure at the NACDS conference indicate the dramatic progress our team has made in the last few months and should make the upcoming launch of our first product an exciting time for PuraMed."
The PuraMed BioScience Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6155
This news release contains forward-looking statements regarding PuraMed BioScience and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.